The UAB Comprehensive Cancer Center is in its 34th year of continuous NCI Core Grant funding. It is a matrix center and has been designated as a University-wide Interdisciplinary Research Center in the University of Alabama at Birmingham organizational structure. Albert F. LoBuglio, M.D., has been Center director since 1983 and reports directly to the University Provost. The Center has 249 members derived from 38 departments and 8 schools of the University. Annual direct research support is $98.8 million with $34.7 million of NCI support, $45.8 million of other peer-reviewed support and $18.2 million of non-peer-reviewed support. The Center is organized into nine major programs: Tumor Immunology, Structural Biology, Virology, Tumor Biology, Experimental Therapeutics, Neuro-Oncology, Women's Cancer, Cancer Chemoprevention, and Cancer Control &Population Science. The Administration component of the Center provides fiscal management of more than 500 accounts (more than $80 million), personnel (464), planning, coordination, and evaluation. The Center provides 15 Core grant supported Shared Facilities involving research technology, biostatistics and bioinformatics, tissue procurement, and patient recruitment and retention. The Cancer Center has 3,444 tumor registry new patient accruals annually and places 779 patients on clinical trials annually including 539 accruals to therapeutic trials in the most recent 12 months. There is an emphasis on investigator-initiated trials and early phase I and II trials. The Center has successfully competed for four SPORE grants in Breast Cancer, Ovarian Cancer, Brain Tumors, and Pancreatic Cancer. The major thrust of the Cancer Control &Population Science Program is minority health disparity with an emphasis on rural, underserved populations in Alabama and Mississippi. In addition, there have been over 24,828 accruals to Cancer Prevention and Control trials over the last funding period primarily related to screening and early detection studies. The Center has had a successful development funding component with recruitment of vital scientific and leadership individuals and an active pilot project program. Internal committees and External Advisory Committee provide advice to the senior leadership of the Center. The Center has strong support by the University and the community with a productive record of successful grant support and scientific publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA013148-38S1
Application #
7922400
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1997-03-28
Project End
2010-03-31
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
38
Fiscal Year
2009
Total Cost
$249,574
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230
Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340
Banerjee, N Sanjib; Wang, Hsu-Kun; Beadle, James R et al. (2018) Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Res 150:164-173
Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34
Kleinpeter, Alex B; Jureka, Alexander S; Falahat, Sally M et al. (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659-14668

Showing the most recent 10 out of 747 publications